tert-Butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate

Catalog No. :
ACTXLB813
CAS No. :
858351-40-3
Molecular Formula :
C17H23FN2O2
Molecular Weight :
306.38

IUPAC Name:tert-butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate

tert-Butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$836.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate
IUPAC Nametert-butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate
MDL No.MFCD20259860
Molecular FormulaC17H23FN2O2
Molecular Weight306.38
SMILESO=C(N1CCC2(CC1)CNC3=C2C=CC(F)=C3)OC(C)(C)C
InChI KeyJUOFAQAYQOGIRU-UHFFFAOYSA-N
Synonymtert-Butyl 6-fluoro-1,2-dihydrospiro[indole-3,4'-piperidine]-1'-carboxylate;tert-Butyl 6-fluorospiro[indoline-3,4'-piperidine]-1'-carboxylate;1,1-Dimethylethyl 6-fluoro-1,2-dihydrospiro[3H-indole-3,4′-piperidine]-1′-carbox…;Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 6-fluoro-1,2-dihydro-, 1,1-dimethylethyl ester
CAS No.858351-40-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACTXLB813 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHFJG807 route compound structure diagram
    ACHFJG8071258638-81-1 In Stock
  2. Then
  3. ACTXLB813 route product structure diagram
    ACTXLB813858351-40-3
Inquiry

2. ACTXLB813 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTXLB813 route product structure diagram
    ACTXLB813858351-40-3
Inquiry

Comments (0)